AbbVie's blockbuster hopeful Orilissa shouldn't be first in line for endometriosis treatment: ICER

7th August 2018 Uncategorised 0

The $845-per-month list price AbbVie set for its just-approved endometriosis drug Orilissa is reasonable enough, a U.S. cost-effectiveness watchdog figures. But payers should consider requiring women to try other treatments first.

More: AbbVie's blockbuster hopeful Orilissa shouldn't be first in line for endometriosis treatment: ICER
Source: fierce